ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : -25 مورد

Cefprozil: Drug information

Cefprozil: Drug information
2025© UpToDate, Inc. and its affiliates and/or licensors. All Rights Reserved.
For additional information see "Cefprozil: Patient drug information" and "Cefprozil: Pediatric drug information"

For abbreviations, symbols, and age group definitions show table
Brand Names: Canada
  • APO-Cefprozil [DSC];
  • Auro-Cefprozil;
  • SANDOZ Cefprozil [DSC];
  • TARO-Cefprozil
Pharmacologic Category
  • Antibiotic, Cephalosporin (Second Generation)
Dosing: Adult
Chronic obstructive pulmonary disease, acute exacerbation

Chronic obstructive pulmonary disease, acute exacerbation: Oral: 500 mg every 12 hours for 5 to 7 days (Ref).

Rhinosinusitis, acute bacterial

Rhinosinusitis, acute bacterial:

Note: In uncomplicated acute bacterial rhinosinusitis, initial observation and symptom management without antibiotic therapy is appropriate in most patients. Reserve antibiotic therapy for poor follow-up or lack of improvement over the observation period (Ref). Cefprozil is not recommended for the empiric treatment of acute bacterial rhinosinusitis because of S. pneumoniae resistance (Ref).

Oral: 250 or 500 mg every 12 hours (Ref); typical duration is 5 to 7 days (Ref).

Skin and soft tissue infection

Skin and soft tissue infection: Oral: 250 or 500 mg every 12 hours or 500 mg every 24 hours (Ref) for 5 days; duration may be extended up to 14 days if not resolved/slow response (Ref).

Streptococcal pharyngitis, group A

Streptococcal pharyngitis, group A (alternative agent):

Note: For patients with penicillin allergy who are able to tolerate cephalosporins. Cephalosporin selection depends on the type of hypersensitivity reaction to penicillin. To avoid the development of resistance, narrower spectrum cephalosporins (eg, cephalexin or cefadroxil) are preferred when possible (Ref).

Oral: 500 mg every 24 hours for 10 days (Ref).

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Adult

Manufacturer's labeling: Oral:

CrCl ≥30 mL/minute: No dosage adjustment necessary.

CrCl <30 mL/minute: Reduce dose by 50%.

End-stage renal disease (ESRD) on hemodialysis: Give dose after dialysis on dialysis days.

Alternative recommendations (Ref): Oral:

Note: Renally adjusted dose recommendations are based on doses of 250 to 500 mg every 12 hours.

CrCl >50 mL/minute: No dosage adjustment necessary.

CrCl <50 mL/minute: Administer 50% of usual dose every 12 hours.

Intermittent hemodialysis (IHD): Supplement with 250 mg after dialysis on dialysis days.

Peritoneal dialysis: Administer 50% of usual dose every 12 hours.

Dosing: Liver Impairment: Adult

No dosage adjustment necessary.

Dosing: Older Adult

Refer to adult dosing.

Dosing: Pediatric

(For additional information see "Cefprozil: Pediatric drug information")

General dosing, susceptible infection (Ref): Infants, Children, and Adolescents: Oral: Mild to moderate infection: 7.5 to 15 mg/kg/dose twice daily; maximum single dose: 500 mg/dose.

Chronic bronchitis, acute bacterial exacerbation

Chronic bronchitis, acute bacterial exacerbation: Adolescents: Oral: 500 mg every 12 hours for 10 days.

Otitis media, acute

Otitis media, acute: Infants ≥6 months and Children: Oral: 15 mg/kg/dose every 12 hours for 10 days; maximum single dose: 500 mg/dose. Note: Cefprozil is not routinely recommended as a treatment option in the acute otitis media guidelines (Ref).

Pharyngitis/tonsillitis

Pharyngitis/tonsillitis:

Children ≥2 years: Oral: 7.5 mg/kg/dose every 12 hours for 10 days; maximum single dose: 500 mg/dose.

Adolescents: Oral: 500 mg every 24 hours for 10 days.

Rhinosinusitis

Rhinosinusitis: Note: The role of cefprozil in the management of acute bacterial sinusitis is limited; other options may be preferred (Ref):

Infants ≥6 months and Children: Oral: 7.5 to 15 mg/kg/dose every 12 hours for 10 days; maximum single dose: 500 mg/dose.

Adolescents: Oral: 250 to 500 mg every 12 hours for 10 days.

Skin and skin structure infection, uncomplicated

Skin and skin structure infection, uncomplicated: Oral:

Children ≥2 years: 20 mg/kg/dose once daily for 10 days; maximum single dose: 500 mg/dose.

Adolescents: 250 mg every 12 hours or 500 mg every 12 to 24 hours for 10 days.

Urinary tract infection

Urinary tract infection: Oral: Infants ≥2 months and Children ≤2 years: 15 mg/kg/dose twice daily for 7 to 14 days (Ref).

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Pediatric

Manufacturer's labeling: Infants ≥6 months, Children, and Adolescents: Oral:

CrCl ≥30 mL/minute: No dosage adjustment necessary.

CrCl <30 mL/minute: Reduce usual recommended dose by 50%.

End-stage renal disease on hemodialysis: Give dose after dialysis on dialysis days.

Alternative recommendations: The following recommendations have been used by some clinicians (Ref): Note: Renally adjusted dose recommendations are based on a usual dose of 30 mg/kg/day divided every 12 hours.

Infants, Children, and Adolescents: Oral:

GFR ≥30 mL/minute/1.73 m2: No dosage adjustment necessary.

GFR <30 mL/minute/1.73 m2: 7.5 mg/kg/dose every 12 hours.

Intermittent hemodialysis: ~55% is removed by hemodialysis; 7.5 mg/kg/dose every 12 hours; administer an additional 5 mg/kg/dose after dialysis session.

Peritoneal dialysis: 7.5 mg/kg/dose every 12 hours.

Dosing: Liver Impairment: Pediatric

Infants, Children and Adolescents: No dosage adjustment necessary

Adverse Reactions

The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.

Frequency not always defined.

1% to 10%:

Central nervous system: Dizziness (1%)

Dermatologic: Diaper rash (2%), genital pruritus (2%)

Gastrointestinal: Nausea (4%), diarrhea (3%), abdominal pain (1%), vomiting (1%)

Genitourinary: Vaginitis

Hepatic: Increased serum transaminases (2%)

Infection: Superinfection

<1%, postmarketing, and/or case reports: Anaphylaxis, angioedema, arthralgia, cholestatic jaundice, confusion, drowsiness, eosinophilia, erythema multiforme, fever, headache, hyperactivity, increased blood urea nitrogen, increased serum creatinine, insomnia, leukopenia, pseudomembranous colitis, serum sickness, skin rash, Stevens-Johnson syndrome, thrombocytopenia, urticaria

Contraindications

Hypersensitivity to cefprozil, any component of the formulation, or other cephalosporins.

Warnings/Precautions

Concerns related to adverse effects:

• Hypersensitivity: If a serious hypersensitivity reaction occurs, discontinue and institute emergency supportive measures, including airway management and treatment (eg, epinephrine, antihistamines and/or corticosteroids).

• Penicillin allergy: Use with caution in patients with a history of penicillin allergy.

• Superinfection: Prolonged use may result in fungal or bacterial superinfection, including C. difficile-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed >2 months postantibiotic treatment.

Disease-related concerns:

• Gastrointestinal disease: Use with caution in patients with a history of gastrointestinal disease, particularly colitis.

• Renal impairment: Use with caution in patients with renal impairment.

Dosage form specific issues:

• Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity ("gasping syndrome") in neonates; the "gasping syndrome" consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP ["Inactive" 1997]; CDC 1982). Some data suggest that benzoate displaces bilirubin from protein-binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates. See manufacturer’s labeling.

• Phenylalanine: Some products may contain phenylalanine.

• Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson, 2002; Lucente 2000; Shelley, 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade, 1986; CDC, 1984). See manufacturer's labeling.

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Suspension Reconstituted, Oral:

Generic: 125 mg/5 mL (50 mL, 75 mL, 100 mL); 250 mg/5 mL (50 mL, 75 mL, 100 mL)

Tablet, Oral:

Generic: 250 mg, 500 mg

Generic Equivalent Available: US

Yes

Pricing: US

Suspension (reconstituted) (Cefprozil Oral)

125 mg/5 mL (per mL): $0.42

250 mg/5 mL (per mL): $0.77

Tablets (Cefprozil Oral)

250 mg (per each): $4.38

500 mg (per each): $9.04

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Suspension Reconstituted, Oral:

Generic: 125 mg/5 mL (50 mL, 75 mL, 100 mL); 250 mg/5 mL (75 mL, 100 mL)

Tablet, Oral:

Generic: 250 mg, 500 mg

Administration: Adult

Oral: Administer without regard to meals.

Administration: Pediatric

Oral: Administer without regard to meals. Shake suspension well before each use.

Use: Labeled Indications

Chronic obstructive pulmonary disease, acute exacerbation: Treatment of mild to moderate acute bacterial exacerbations of chronic bronchitis caused by Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis.

Otitis media: Treatment of mild to moderate otitis media caused by S. pneumoniae, H. influenzae, and M. catarrhalis.

Limitations of use: Cefprozil had bacteriologic eradication rates somewhat lower than those observed with a product containing a specific beta-lactamase inhibitor in the treatment of otitis media due to beta-lactamase producing organisms.

Rhinosinusitis, acute bacterial: Treatment of mild to moderate acute bacterial rhinosinusitis caused by S. pneumoniae, H. influenzae, and M. catarrhalis. Note: Clinical practice guidelines do not recommend cefprozil as initial empiric treatment of acute bacterial rhinosinusitis due to variable rates of resistance among S. pneumoniae (Ref).

Skin and soft tissue infection: Treatment of mild to moderate uncomplicated skin and skin-structure infections caused by Staphylococcus aureus and S. pyogenes.

Streptococcal pharyngitis, group A: Treatment of mild to moderate pharyngitis/tonsillitis caused by Streptococcus pyogenes.

Limitations of use: Cefprozil is generally effective in the eradication of S. pyogenes from the nasopharynx; however, substantial data establishing the efficacy of cefprozil in the subsequent prevention of rheumatic fever are not available at present.

Medication Safety Issues
Sound-alike/look-alike issues:

Cefprozil may be confused with ceFAZolin, cefuroxime

Cefzil may be confused with Ceftin

Metabolism/Transport Effects

Substrate of OAT1/3;

Drug Interactions

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the drug interactions program by clicking on the “Launch drug interactions program” link above.

Aminoglycosides: Cephalosporins may increase nephrotoxic effects of Aminoglycosides. Cephalosporins may decrease serum concentration of Aminoglycosides. Risk C: Monitor

Bacillus clausii: Antibiotics may decrease therapeutic effects of Bacillus clausii. Management: Bacillus clausii should be taken in between antibiotic doses during concomitant therapy. Risk D: Consider Therapy Modification

BCG (Intravesical): Antibiotics may decrease therapeutic effects of BCG (Intravesical). Risk X: Avoid

BCG Vaccine (Immunization): Antibiotics may decrease therapeutic effects of BCG Vaccine (Immunization). Risk C: Monitor

Cholera Vaccine: Antibiotics may decrease therapeutic effects of Cholera Vaccine. Management: Avoid cholera vaccine in patients receiving systemic antibiotics, and within 14 days following the use of oral or parenteral antibiotics. Risk X: Avoid

Fecal Microbiota (Live) (Oral): May decrease therapeutic effects of Antibiotics. Risk X: Avoid

Fecal Microbiota (Live) (Rectal): Antibiotics may decrease therapeutic effects of Fecal Microbiota (Live) (Rectal). Risk X: Avoid

Furosemide: May increase nephrotoxic effects of Cephalosporins. Risk C: Monitor

Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies): Antibiotics may decrease therapeutic effects of Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies). Risk C: Monitor

Lactobacillus and Estriol: Antibiotics may decrease therapeutic effects of Lactobacillus and Estriol. Risk C: Monitor

Mycophenolate: Antibiotics may decrease active metabolite exposure of Mycophenolate. Specifically, concentrations of mycophenolic acid (MPA) may be reduced. Risk C: Monitor

Probenecid: May increase serum concentration of Cephalosporins. Risk C: Monitor

Sodium Picosulfate: Antibiotics may decrease therapeutic effects of Sodium Picosulfate. Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic. Risk D: Consider Therapy Modification

Typhoid Vaccine: Antibiotics may decrease therapeutic effects of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected. Management: Avoid use of live attenuated typhoid vaccine (Ty21a) in patients being treated with systemic antibacterial agents. Postpone vaccination until 3 days after cessation of antibiotics and avoid starting antibiotics within 3 days of last vaccine dose. Risk D: Consider Therapy Modification

Vitamin K Antagonists: Cephalosporins may increase anticoagulant effects of Vitamin K Antagonists. Risk C: Monitor

Food Interactions

Food delays cefprozil absorption. Management: May administer with food.

Pregnancy Considerations

Adverse events were not observed in animal reproduction studies.

Breastfeeding Considerations

Small amounts of cefprozil are excreted in breast milk. The manufacturer recommends that caution be exercised when administering cefprozil to nursing women. Nondose-related effects could include modification of bowel flora.

Dietary Considerations

Some products may contain phenylalanine.

Monitoring Parameters

Monitor renal function at baseline and as clinically indicated. Monitor for signs of anaphylaxis during first dose.

Mechanism of Action

Inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins (PBPs) which in turn inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thus inhibiting cell wall biosynthesis. Bacteria eventually lyse due to ongoing activity of cell wall autolytic enzymes (autolysins and murein hydrolases) while cell wall assembly is arrested.

Pharmacokinetics (Adult Data Unless Noted)

Absorption: Well absorbed (95%).

Distribution: Vd: 0.23 L/kg.

Protein binding: ~36%.

Bioavailability: 95%.

Half-life elimination:

Infants ≥6 months and Children: 1.5 hours.

Adults:

Normal: 1.3 hours.

Kidney impairment: Up to 5.2 hours (dependent upon degree of kidney impairment).

Kidney failure: Up to 5.9 hours.

Hepatic impairment: ~2 hours.

Time to peak, serum:

Infants ≥6 months and Children: 1 to 2 hours.

Adult: Fasting: 1.5 hours.

Excretion: Urine (~60% as unchanged drug).

Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)

Older adult: AUC is about 35% to 60% higher.

Anti-infective considerations:

Parameters associated with efficacy: Time dependent; associated with time free drug concentration (fT) > minimum inhibitory concentration (MIC): Goal: ≥40% to 50% (fT) > MIC (bacteriostatic), ≥60% to 70% (fT) > MIC (bactericidal) (Craig 1996; Craig 1998; Turnidge 1998).

Expected drug exposure in patients with normal renal function:

Pediatric patients, Cmax (peak):

Steady state: Infants ≥6 months of age and children ≤4 years of age: 15 mg/kg/dose twice daily: 9.18 mg/L (Nicolau 2007).

Single dose: Infants ≥8 months of age and children:

15 mg/kg, single dose: 11.16 ± 2.45 mg/L (Sáez-Llorens 1990).

30 mg/kg, single dose: 15.93 ± 3.22 mg/L (Sáez-Llorens 1990).

Adults, Cmax (peak): 500 mg twice daily, steady state: 10.4 ± 1.3 mg/L (Barbhaiya 1990).

Postantibiotic effect: Generally <1 hour; varies based on organism (Craig 1991; Craig 1998).

Brand Names: International
International Brand Names by Country
For country code abbreviations (show table)

  • (AE) United Arab Emirates: Cefproz | Cefzil;
  • (AR) Argentina: Procef;
  • (BD) Bangladesh: Cefozil | Zilapro;
  • (BG) Bulgaria: Cefsil | Cefzill | Profix;
  • (BR) Brazil: Cefzil;
  • (CH) Switzerland: Procef;
  • (CN) China: Cefzil | Kai ke zhi | Shi fu jie | Xi neng;
  • (CO) Colombia: Procef;
  • (CZ) Czech Republic: Cefzil;
  • (DO) Dominican Republic: Procef;
  • (EC) Ecuador: Procef;
  • (EE) Estonia: Cefzil | Pricefil;
  • (EG) Egypt: Cefzil | Zilospore;
  • (ES) Spain: Arzimol | Brisoral;
  • (ET) Ethiopia: Cefproz | Cefprozil;
  • (GR) Greece: Cefgram | Cefium | Cefpro | Cefzil | Natrofen | Pricefil | Procef | Prozidil | Sanocef | Teliomon | Top 1 | Zamalin;
  • (HR) Croatia: Cefzil;
  • (HU) Hungary: Cefzil;
  • (ID) Indonesia: Cefzil | Lizor;
  • (IN) India: 3cef | Orprozil | Refzil o | Zalozil | Zemetril;
  • (IT) Italy: Cronocef | Procef | Prolizip | Rozicel;
  • (JO) Jordan: Aurozil | Cefzil | Quzil;
  • (KE) Kenya: Aurozil | Zilab;
  • (KR) Korea, Republic of: Anaprozil | Cefazil | Cefil | Cefirozil | Cefozil | Cefpro | Cefpron | Cefpzil | Cefran | Cefrogen | Cefron | Cefrozil | Cefuzil | Cefzil | Cepazil | Cephizin | Cepirozil | Cepro | Ceprozima | Cerant | Cerofazil | Cerofazzil | Cerop | Cesilpro | Cexilpro | Kingcef | Kyongbo cefprozil | Neocezil | Procef | Procezil | Prozil | Rozicef | Sama cefprozil | Twocef | Wiprozil;
  • (KW) Kuwait: Cefzil;
  • (LB) Lebanon: Cefproz | Cefzil;
  • (LT) Lithuania: Cefzil | Refzil o;
  • (LV) Latvia: Cefzil;
  • (MX) Mexico: Procef;
  • (PE) Peru: Citofer;
  • (PH) Philippines: Procef;
  • (PK) Pakistan: Cefozil | Cefproz | Ceftru | Proceph | Proceph ds | Vegapro | Zilocef | Zuropil;
  • (PL) Poland: Cefzil;
  • (PR) Puerto Rico: Cefprozil | Cefzil;
  • (PT) Portugal: Procef | Radacefe;
  • (QA) Qatar: Cefproz;
  • (RO) Romania: Cefzil;
  • (SA) Saudi Arabia: Apo cefprozil | Cefproz | Cefzil;
  • (SG) Singapore: Procef;
  • (SI) Slovenia: Cefzil;
  • (SK) Slovakia: Cefzil;
  • (TH) Thailand: Procef;
  • (TR) Turkey: Erasef | Prefix | Serozil | Ultracef | Zilcef;
  • (VE) Venezuela, Bolivarian Republic of: Procef;
  • (VN) Viet Nam: Brodicef | Cefdiri | Cerepone | Dopharalgic | Pharbaren | Toprozil;
  • (ZA) South Africa: Auroprozil | Lizorp | Prozef
  1. Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. J Pediatr. 2001;139(2):317-319. [PubMed 11487763]
  2. Alade SL, Brown RE, Paquet A Jr. Polysorbate 80 and E-Ferol toxicity. Pediatrics. 1986;77(4):593-597. [PubMed 3960626]
  3. American Academy of Pediatrics (AAP). In: Kimberlin DW, Brady MT, Jackson MA, Long SA, eds. Red Book: 2018 Report of the Committee on Infectious Diseases. 31st ed. Itasca, IL: American Academy of Pediatrics; 2018.
  4. American Academy of Pediatrics. Urinary tract infection: clinical practice guideline for the diagnosis and management of the initial UTI in febrile infants 2 to 24 months. Pediatrics. 2011;128(3):595-610. http://pediatrics.aappublications.org/content/128/3/595.full. [PubMed 21873693]
  5. Arguedas AG, Zaleska M, Stutman HR, et al, “Comparative Trial of Cefprozil vs Amoxicillin Clavulanate Potassium in the Treatment of Children With Acute Otitis Media With Effusion,” Pediatr Infect Dis J, 1991, 10(5):375-80. [PubMed 1906160]
  6. Aronoff GR, Bennett WM, Berns JS, et al. Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children. 5th ed. Philadelphia, PA: American College of Physicians; 2007.
  7. Barbhaiya RH, Shukla UA, Gleason CR, et al. Phase I study of multiple-dose cefprozil and comparison with cefaclor. Antimicrob Agents Chemother. 1990;34(6):1198-1203. doi:10.1128/AAC.34.6.1198 [PubMed 2393281]
  8. Barriere SL, “Review of In Vitro Activity, Pharmacokinetic Characteristics, Safety, and Clinical Efficacy of Cefprozil, a New Oral Cephalosporin,” Ann Pharmacother, 1993, 27(9):1082-9. [PubMed 8219444]
  9. Bradley JS, Byington CL, Shah SS, et al. “The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America”, Clin Infect Dis, 2011, 53(7):e25-76. [PubMed 21880587]
  10. Cefprozil [prescribing information]. Princeton, NJ: Sandoz Inc; May 2014.
  11. Cefprozil powder for suspension [prescribing information]. East Windsor, NJ: Aurobindo Pharma USA, Inc; September 2019.
  12. Cefprozil tablet [prescribing information]. Parsippany, NJ: Alkem Laboratories Ltd; November 2020.
  13. Cefzil (cefprozil) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; November 2016.
  14. Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. MMWR Morb Mortal Wkly Rep. 1982;31(22):290-291. http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm [PubMed 6810084]
  15. Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. MMWR Morb Mortal Wkly Rep. 1984;33(14):198-199. http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm. [PubMed 6423951]
  16. Chow AW, Benninger MS, Brook I, et al. IDSA Clinical Practice Guideline for Acute Bacterial Rhinosinusitis in Children and Adults. Clin Infect Dis. 2012;54(8):e72-e112. [PubMed 22438350]
  17. Craig WA, Andes D. Pharmacokinetics and pharmacodynamics of antibiotics in otitis media. Pediatr Infect Dis J. 1996;15(3):255-259. doi:10.1097/00006454-199603000-00015 [PubMed 8852915]
  18. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis. 1998;26(1):1-10. doi:10.1086/516284 [PubMed 9455502]
  19. Craig WA. The postantibiotic effect. CMNEEJ. 1991;13(16)121-128.
  20. Gainer RB 2nd, “Cefprozil: A New Cephalosporin; Its Use in Various Clinical Trials,” South Med J, 1995, 88(3):338-46. [PubMed 7886533]
  21. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: 2024 report. https://goldcopd.org/2024-gold-report/. Updated 2024. Accessed April 3, 2025.
  22. Harris AM, Hicks LA, Qaseem A; High Value Care Task Force of the American College of Physicians and for the Centers for Disease Control and Prevention. Appropriate antibiotic use for acute respiratory tract infection in adults: advice for high-value care from the American College of Physicians and the Centers for Disease Control and Prevention. Ann Intern Med. 2016;164(6):425-434. doi:10.7326/M15-1840 [PubMed 26785402]
  23. "Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. Pediatrics. 1997;99(2):268-278. [PubMed 9024461]
  24. Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. Contact Dermatitis. 2002;47(5):312-313.
  25. Lieberthal AS, Carroll AE, Chonmaitree T, et al. The diagnosis and management of acute otitis media. Pediatrics. 2013;131(3):e964-999. [PubMed 23439909]
  26. Lowery N, Kearns GL, Young RA, et al, “Serum Sickness-Like Reactions Associated With Cefprozil Therapy,” J Pediatr, 1994, 125(2):325-8. [PubMed 8040786]
  27. Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. Contact Dermatitis. 2000;43(3):172. [PubMed 10985636]
  28. Marshall WF and Blair JE, “The Cephalosporins,” Mayo Clin Proc, 1999, 74(2):187-95. [PubMed 10069359]
  29. Nicolau DP, Sutherland CA, Arguedas A, Dagan R, Pichichero ME. Pharmacokinetics of cefprozil in plasma and middle ear fluid: in children undergoing treatment for acute otitis media. Paediatr Drugs. 2007;9(2):119-123. doi:10.2165/00148581-200709020-00005 [PubMed 17407367]
  30. Refer to manufacturer's labeling.
  31. Rosenfeld RM, Piccirillo JF, Chandrasekhar SS, et al. Clinical practice guideline (update): Adult Sinusitis Executive Summary. Otolaryngol Head Neck Surg. 2015;152(4):598-609. doi:10.1177/0194599815574247 [PubMed 25833927]
  32. Sáez-Llorens X, Shyu WC, Shelton S, Kumiesz H, Nelson J. Pharmacokinetics of cefprozil in infants and children. Antimicrob Agents Chemother. 1990;34(11):2152-2155. doi:10.1128/AAC.34.11.2152 [PubMed 2073105]
  33. Schatz BS, Karavokiros KT, Taeubel MA, et al, “Comparison of Cefprozil, Cefpodoxime Proxetil, Loracarbef, Cefixime, and Ceftibuten,” Ann Pharmacother, 1996, 30(3):258-68. [PubMed 8833562]
  34. Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. Lancet. 1995;345(8980):1312-1313. [PubMed 7746084]
  35. Shukla UA, Pittman KA, and Barbhaiya RH, “Pharmacokinetic Interactions of Cefprozil With Food, Propantheline, Metoclopramide, and Probenecid in Healthy Volunteers,” J Clin Pharmacol, 1992, 32(8):725-31. [PubMed 1487562]
  36. Shulman ST, Bisno AL, Clegg HW, et al. Clinical practice guideline for the diagnosis and management of group A streptococcal pharyngitis: 2012 update by the Infectious Diseases Society of America. Clin Infect Dis. 2012;55(10):e86-e102. doi:10.1093/cid/cis629 [PubMed 22965026]
  37. Shyu WC, Pittman KA, Wilber RB, et al, “Pharmacokinetics of Cefprozil in Healthy Subjects and Patients With Hepatic Impairment,” J Clin Pharmacol, 1991, 31(4):372-6. [PubMed 2037711]
  38. Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis. 2014;59(2):e10-e52. doi:10.1093/cid/ciu444 [PubMed 24973422]
  39. Turnidge JD. The pharmacodynamics of beta-lactams. Clin Infect Dis. 1998;27(1):10-22. doi:10.1086/514622 [PubMed 9675443]
Topic 9225 Version 300.0